A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder
- PMID: 22864465
- PMCID: PMC4624319
- DOI: 10.1176/appi.ajp.2012.12010009
A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder
Abstract
Objective: Antidepressants targeting monoaminergic neurotransmitter systems, despite their immediate effects at the synaptic level, usually require several weeks of administration to achieve clinical efficacy. The authors propose a strategy of adding creatine monohydrate (creatine) to a selective serotonin reuptake inhibitor (SSRI) in the treatment of patients with major depressive disorder. Such augmentation may lead to a more rapid onset of antidepressant effects and a greater treatment response, potentially by restoring brain bioenergetics at the cellular level.
Method: Fifty-two women with major depressive disorder were enrolled in an 8-week double-blind placebo-controlled clinical trial and randomly assigned to receive escitalopram in addition to either creatine (5 g/day, N=25) or placebo (N=27). Efficacy was primarily assessed by changes in the Hamilton Depression Rating Scale (HAM-D) score.
Results: In comparison to the placebo augmentation group, patients receiving creatine augmentation showed significantly greater improvements in HAM-D score, as early as week 2 of treatment. This differential improvement favoring creatine was maintained at weeks 4 and 8. There were no differences between treatment groups in the proportion of patients who discontinued treatment prematurely (creatine: N=8, 32.0%; placebo: N=5, 18.5%) or in the overall frequency of all reported adverse events (creatine: 36 events; placebo: 45 events).
Conclusions: The current study suggests that creatine augmentation of SSRI treatment may be a promising therapeutic approach that exhibits more rapid and efficacious responses in women with major depressive disorder.
Trial registration: ClinicalTrials.gov NCT00729755.
Figures
![FIGURE 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4624319/bin/nihms-728384-f0001.gif)
![FIGURE 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4624319/bin/nihms-728384-f0002.gif)
Comment in
-
Bioenergetics for depression: something different for depression.Am J Psychiatry. 2012 Sep;169(9):891-3. doi: 10.1176/appi.ajp.2012.12050720. Am J Psychiatry. 2012. PMID: 22952068 No abstract available.
Similar articles
-
Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder.Biol Psychiatry. 2016 Sep 15;80(6):439-447. doi: 10.1016/j.biopsych.2015.11.027. Epub 2015 Dec 15. Biol Psychiatry. 2016. PMID: 26822799 Clinical Trial.
-
A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression.Int Clin Psychopharmacol. 2013 May;28(3):127-33. doi: 10.1097/YIC.0b013e32835ff20f. Int Clin Psychopharmacol. 2013. PMID: 23466591 Clinical Trial.
-
An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women.J Clin Psychopharmacol. 2017 Oct;37(5):578-583. doi: 10.1097/JCP.0000000000000754. J Clin Psychopharmacol. 2017. PMID: 28787372 Free PMC article. Clinical Trial.
-
Escitalopram : a review of its use in the management of major depressive and anxiety disorders.CNS Drugs. 2003;17(5):343-62. doi: 10.2165/00023210-200317050-00004. CNS Drugs. 2003. PMID: 12665392 Review.
-
[Efficacy and tolerability of escitalopram in anxiety disorders: a review].Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Encephale. 2008. PMID: 18922243 Review. French.
Cited by
-
"Heads Up" for Creatine Supplementation and its Potential Applications for Brain Health and Function.Sports Med. 2023 Dec;53(Suppl 1):49-65. doi: 10.1007/s40279-023-01870-9. Epub 2023 Jun 27. Sports Med. 2023. PMID: 37368234 Free PMC article. Review.
-
A Randomized Controlled Trial of Changes in Fluid Distribution across Menstrual Phases with Creatine Supplementation.Nutrients. 2023 Jan 13;15(2):429. doi: 10.3390/nu15020429. Nutrients. 2023. PMID: 36678300 Free PMC article. Clinical Trial.
-
BDNF as a Mediator of Antidepressant Response: Recent Advances and Lifestyle Interactions.Int J Mol Sci. 2022 Nov 21;23(22):14445. doi: 10.3390/ijms232214445. Int J Mol Sci. 2022. PMID: 36430921 Free PMC article. Review.
-
Active Women Across the Lifespan: Nutritional Ingredients to Support Health and Wellness.Sports Med. 2022 Dec;52(Suppl 1):101-117. doi: 10.1007/s40279-022-01755-3. Epub 2022 Sep 29. Sports Med. 2022. PMID: 36173598 Free PMC article. Review.
-
Effects of Creatine Supplementation on Brain Function and Health.Nutrients. 2022 Feb 22;14(5):921. doi: 10.3390/nu14050921. Nutrients. 2022. PMID: 35267907 Free PMC article. Review.
References
-
- Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes:m a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):5–9. - PubMed
-
- Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292:338–343. - PubMed
-
- Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K, Gardner D, Faulding J, Madeley R. Deliberate self-harm and antidepressant drugs: investigation of a possible link. Br J Psychiatry. 2000;177:551–556. - PubMed
-
- Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol. 1993;3:127–135. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical